Productivity loss of Japanese patients with rheumatoid arthritis – A cross-sectional survey

References

• Zhang W, Bansback N, Beaton D, Lacaille D, Gignac M, Badley E, Bombardier C, Anis AH, How is reduced performance at work (presenteeism) associated with measures of disease severity in patients with osteoarthritis (OA) and rheumatoid arthritis (RA)? [abstract]. Ann Rheum Dis. 2008;67:583.
   Google Scholar
• Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine. 2004;71(6):518–24.
   PubMed Web of Science ®Google Scholar
• Benucci M, Rogai V, Atzeni F, Hammen V, Sarzti-Puttini P, Migliore A. Costs associated with rheumatoid arthritis in Italy: past, present, and future. Clinicoecon Outcomes Res. 2016;8:33–41.
   PubMed Web of Science ®Google Scholar
• Huscher D, Mittendorf T, von Hinüber U, Kötter I, Hoese G, Pfäfflin A, et al. Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis. 2015;74(4):738–45.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Hoshi D, Igarashi A, Inoue E, Shidara K, Sugimoto N, et al. Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Mod Rheumatol. 2013;23(4):742–51.
   PubMed Web of Science ®Google Scholar
• Yelin E. The cost of rheumatoid arthritis: absolute, incremental and marginal estimates. J Rheumatol Suppl. 1996;44(44):47–51.
   PubMedGoogle Scholar
• The Impact of Arthritis in Canada. Today and Over the Next 30 Years. Available from: http://can.arthritisalliance.ca/about-2/can-s-history-as-an-nce/news-archive/the-impact-of-arthritis-in-canada-today-and-over-the-next-30-years.
   Google Scholar
• Thanh N, Ohinmaa A, Barnabe C, Homik J, Barr S, Martin L, Maksymowych W. Self-reported productivity losses of people with rheumatoid arthritis in Alberta, Canada. Topharmej. 2013; 5:11–14.
   Google Scholar
• Klimeš J, Vocelka M, Šedová L, Dolezal T, Mlcoch T, Petríková A, Vlcek J. Medical and productivity costs of rheumatoid arthritis in The Czech Republic: cost-of-illness study based on disease severity. Value Health Regional Issues. 2014;4:75–81.
   PubMedGoogle Scholar
• Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. For the German Collaborative Arthritis Centres: Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006;65(9):1175–83.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2014;24(1):33–40.
   PubMed Web of Science ®Google Scholar
• Addae H, Johns G, Boies K. The legitimacy of absenteeism from work: a nine nation exploratory study. Cross Cultural Manag. 2013;20(3):402–28.
   Google Scholar
• Kanai A. ‘Karoshi (Work to Death)’ in Japan. J Bus Ethics. 2009;84:209.
   Web of Science ®Google Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the stanford health assessment questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;46(6):784–8.
   Web of Science ®Google Scholar
• Ochiai M, Tanaka E, Inoue E, Yamaguchi R, Shimizu Y, Sugimoto N, Ikari K, Nakajima A, Taniguchi A, Yamanaka H. FRI0117 chronological changes in achieving j-haq remission in patients with early-stage rheumatoid arthritis in the iorra cohort. Ann Rheum Dis. 2017;76:524–5.
   Web of Science ®Google Scholar
• Shidara K, Nakajima A, Inoue E, Hoshi D, Sugimoto N, Seto Y, et al. The minimally important difference for the Japanese version of the health assessment questionnaire in patients with rheumatoid arthritis in daily practice. Mod Rheumatol. 2017;27(3):430–4.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Inoue E, Shimizu Y, Am K, Sugimoto N, Hoshi D, Shidara K. Optimal rheumatoid arthritis patient selection for biological treatment from pharmacoeconomic perspectives based on the institute of rheumatology, rheumatoid arthritis (IORRA) cohort. Arthritis Rheum. 2013;65(Suppl 10):1344.
   Google Scholar
• Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Kumei S, Ohhira M, Nozu T, Okumura T. Screening for major depressive disorder with the patient health questionnaire (PHQ-9 and PHQ-2) in an outpatient clinic staffed by primary care physicians in Japan: a case control study. PLoS One. 2015;10(3):e0119147.
   PubMed Web of Science ®Google Scholar
• Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep. 2008;10(3):258–64.
   PubMedGoogle Scholar
• Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013;52(12):2136–48.
   PubMed Web of Science ®Google Scholar
• Chaparro del Moral R, Rillo O, Casalla L, Moron CB, Citera G, Cocco JA, et al. Work Productivity in rheumatoid arthritis: relationship with clinical and radiological features. Arthritis. 2012;1012:137635.
   Google Scholar
• Bank of Japan. Statistics. Tokyo 2017. Available from: https://www.boj.or.jp/en/statistics/index.htm/.
   Google Scholar
• Statistics Japan. Family income and expenditures. Tokyo 2017. Available from: http://www.stat.go.jp/english/data/nenkan/1431-22.htm.
   Google Scholar
• Zhang W, Anis AH. The economic burden of rheumatoid arthritis: beyond health care costs. Clin Rheumatol. 2011;30(Suppl 1):S25–32.
   PubMed Web of Science ®Google Scholar
• Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care. 2006;44(4):304–10.
   PubMed Web of Science ®Google Scholar
• Burton W, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond). 2006;56(1):18–27.
   PubMed Web of Science ®Google Scholar
• Sokka T, Pincus T. Markers for work disability in rheumatoid arthritis. J Rheumatol. 2001;28(7):1718–22.
   PubMed Web of Science ®Google Scholar
• De Croon E, Sluiter J, Nijssen T, Dijkmans B, Lankhorst G, Frings-Dresen H. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2004;63(11):1362–7.
   PubMed Web of Science ®Google Scholar
• Barra L, Ha A, Sun L, Fonseca C, Pope J. Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons. Clin Exp Rheumatol. 2014;32(3):333–41.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, et al. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2013;65(10):1666–73.
   PubMed Web of Science ®Google Scholar
• Carter L, Nasuda K. An overview of Japanese employment law. Ela Briefing. 2014;21(1):13–14.
   Google Scholar
• Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 2005;52(1):36–41.
   PubMed Web of Science ®Google Scholar
• Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford). 2010;49(10):1900–10.
   PubMed Web of Science ®Google Scholar
• Emery P, Smolen JS, Ganguli A, Meerwein S, Bao Y, Kupper H, et al. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. Rheumatology (Oxford). 2016;55(8):1458–65.
   PubMed Web of Science ®Google Scholar
• Han C, Kavanaugh A, Genovese M, Deodhar A, Hsu B, Hsia E. Sustained improvement in health related quality of life, work productivity, employability, and reduced healthcare resource utilization of patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with golimumab:5yr results. Ann Rheum Dis. 2013;72:A337.
   PubMed Web of Science ®Google Scholar
• Asami Y, Goren A, Okumura Y. Work productivity loss with depression, diagnosed and undiagnosed, among workers in an Internet-based survey conducted in Japan. J Occup Environ Med. 2015;57(1):105–10.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Choi H, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol. 2005;32(10):1875–83.
   PubMed Web of Science ®Google Scholar
• Lee H, Iijima Y, Reade C. Employee preference for performance-related pay: predictors and consequences for organizational citizenship behaviour in a Japanese firm. Int J Hum Resour Manag. 2011;22(10):2086–109.
   Web of Science ®Google Scholar